Ria et al. (2014) demonstrated that downregulation of HIF-1α in MM BM endothelial cells could inhibit angiogenesis and restore the sensitivity of bortezomib and lenalidomide. The gene discussed is HIF1A; the disease is Miyoshi myopathy.